Trump Secures Drug Pricing Deals With Nine Pharma Companies 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
GM Canada Workers Approve C$1.1 Billion Investment Deal 
Trump Says ExxonMobil Among Oil Majors Planning Venezuela Return 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
CIA-Linked Investor Helped Quantum Systems Expand in US 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
MediaTek Shares Jump 10% on Nvidia’s $3.5 Billion Investment 
South Korea Unveils Record $597 Billion 2027 Budget to Boost AI and Chips 
Shein Shares Slide 9% in Hong Kong IPO Debut 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Add as a preferred source on Google
SOUTH SAN FRANCISCO, Calif., March 14, 2018 -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the Company will present at two upcoming investor conferences.
Willie Quinn, Chief Financial Officer and Senior Vice President, Finance and Corporate Development of Sunesis, will present at the Oppenheimer 28th Annual Healthcare Conference on Wednesday, March 21, 2018 at 8:35 AM Eastern Time at the Westin Grand Central Hotel in New York City.
Mr. Quinn will also present at the Needham & Company’s 17th Annual Healthcare Conference on Tuesday, March 27, 2018 at 8:00 AM Eastern Time at the Westin Grand Central Hotel in New York City.
Live webcasts of the presentations will be available on the Sunesis website at http://ir.sunesis.com. A replay of each webcast will be archived on the "Calendar of Events" page in the Investors and Media section of the Sunesis website for two weeks.
About Sunesis Pharmaceuticals
Sunesis is a biopharmaceutical company developing new therapeutics for the treatment of solid and hematologic cancers. Sunesis has built an experienced cancer drug development organization committed to improving the lives of people with cancer. The Company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept that its oral non-covalent BTK-inhibitor vecabrutinib is effective in ibrutinib-resistant chronic lymphocytic leukemia. Vecabrutinib is currently being evaluated in a Phase 1b/2 study in adults with chronic lymphocytic leukemia and other B-cell malignancies who have progressed after prior therapies. Beyond the development of vecabrutinib, the Company has two other kinase inhibitor programs, including the Takeda-partnered pan-RAF inhibitor TAK-580, which is in clinical trials for solid tumors, and Sunesis’ proprietary preclinical PDK1 inhibitor SNS-510, which is in preclinical development with an IND submission planned in 2019. PDK1 is a master kinase that activates other kinases important to cell growth and survival including members of the AKT, PKC, RSK and SGK families.
For additional information on Sunesis, please visit www.sunesis.com.
SUNESIS and the logos are trademarks of Sunesis Pharmaceuticals, Inc.
| Investor and Media Inquiries: Maeve Conneighton Argot Partners 212-600-1902 | Willie Quinn Sunesis Pharmaceuticals Inc. 650-266-3716 | ||
